At a Glance
- Companies: Novartis; Zonsen PepLib Biotech Inc.
- Location: Basel, Switzerland (Novartis); Hunan, China (PepLib)
- Deal value: $50m upfront; undisclosed milestones; tiered royalties on global net sales
- Focus area: Peptide‑based radioligand therapy (RLT) asset for oncology
- Next steps: Novartis leads global development and commercialisation
What happened?
Novartis has entered an exclusive worldwide licence agreement with Zonsen PepLib Biotech for an undisclosed peptide‑based radioligand therapy (RLT) asset. PepLib receives a $50 million upfront payment and is eligible for development, regulatory and sales milestone payments plus tiered royalties on future global net sales, with Novartis assuming full responsibility for research, development and commercialisation.
Why does it matter?
The RLT market is exploding from $8.5 billion in 2025 to a projected $25 billion by 2030 at 18% CAGR, driven by precision targeting of tumours with radioligands like Novartis’ Pluvicto ($2.3bn sales) and Lutathera ($1.8bn). PepLib’s peptide platform supports PRCs, POCs and PDCs for oncology/cardiometabolic diseases, complementing Novartis’ infrastructure for new tumour types or improved dosing.
Who’s behind it?
Zonsen PepLib Biotech is a Hunan‑based firm with proprietary peptide libraries and discovery for oncology modalities including peptide radionuclide conjugates (PRCs). Novartis leads RLTs with GMP sites in New Jersey, Italy and China, positioning it to scale the asset rapidly.
How was it achieved?
PepLib, having developed the asset in‑house, grants Novartis exclusive global rights; Novartis leverages its RLT expertise for IND‑enabling studies (2027 target), phase 1/2 trials (2028–2030) and global launches (2031+). Total value could reach $850m including milestones/royalties, aligning with recent RLT deals.
What’s next?
Novartis will advance preclinical validation and clinical development, potentially complementing its PSMA/SSTR RLTs. PepLib uses proceeds to expand its oncology platform for additional partnerships.
What are people saying?
PepLib representatives called it a validation of its peptide RLT capabilities. Novartis views it as strengthening its oncology leadership with next‑gen radioligands. Analysts note Chinese biotech’s rising global validation in complex modalities.